AriBio AR1001-Polaris Clinical trial of investigational drug for Alzheimer

Trial ID:
IRB-24-8373
Leonard Sokol, MD

Inclusion Criteria

Patients must:

  • Be male or female aged 55-90 years of age
    Have mild cognitive impairment or mild dementia with Alzheimer’s
    Be willing to comply with study requirements (participants and caregiver(s)
    Meet all other eligibility criteria

Exclusion Criteria

Patients must not:

  • Be pregnant, nursing, or of childbearing potential and not practicing effective contraception
    Have signs of significant delirium which would interfere with this study
    Have any diagnosis of dementia or cognitive decline other than that related to AD,
    Have any current psychiatric disorder
    Have a history of vascular dementia or evidence of other neurological conditions thought to interfere with the evaluations in this study
    Have a history of myocardial infarction, unstable angina, coronary artery disease and heart failure within the last 12 months

Additional Info

Eligible participants will be randomized, like the flip of a coin, to receive the investigational drug AR1001 or a placebo (no active ingredients).

Total study duration is expected to be about 52 weeks.

For more information search NCT05531526 at https://www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org